NEW YORK, April 11 - Genmab and Paradigm Therapeutics today said they plan to co-develop new antibody therapeutics.

The partners will combine Paradigm's disease targets and bioinformatics platform with Genmab's fully human antibody technology to develop therapeutics for cancer, inflammatory diseases, and other states.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.